Dactinomycin

Products

Dactinomycin was commercially available as a lyophilizate (Cosmegen). It was approved in many countries since 1966 and was withdrawn from the market in 2012 on November 30 for commercial reasons. It can be imported from abroad if needed.

Structure and properties

Dactinomycin (C₆₂H₈₆N₁₂O₁₆, M_r = 1255.4 g/mol) is an actinomycin and phenoxazone derivative formed by.

Effects

Dactinomycin (ATC L01DA01) is antineoplastic. Its effects are due to binding to DNA and inhibition of RNA synthesis. Dactinomycin also has antibacterial properties but is too toxic to be used as an antibiotic.

Indications

• Wilms tumor, infantile rhabdomyosarcoma, Ewing sarcoma, and metastatic testicular carcinoma.
• Chorionic carcinoma
• Malignant melanoma